Back to shop

Peptide · Research use only

Selank

$64CAD

A tuftsin-derived heptapeptide explored in stress-response, GABA-related and intranasal neurobiology research.

Available to approved purchasers

Select strength
1
Documentation review pending Fulfilled in Canada Research use only

Can’t find the right record?Send support the product name or batch code.

Contact support
Selank$64

Product information

Selank, clearly explained.

A tuftsin-derived heptapeptide explored in stress-response, GABA-related and intranasal neurobiology research.

Overview

Selank has a small comparative human study and a wider mechanistic literature, much of it from animal or laboratory models. Independent replication, route-specific safety and clinically meaningful outcomes remain insufficiently established.

Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived from the immunomodulatory peptide tuftsin and appears in a limited body of human, animal and laboratory research.
Format
Nasal spray
Available strengths
10mg
Documentation
Source review pending
Research at a glanceOne small comparative human study plus preclinical mechanistic evidence
Reviewed 31 July 2026View research context

Specifications

Product details

Sequence / identity
TKPRPGP
Molecular formula
C33H57N11O9
Molecular weight
751.9 g/mol
Storage and handling
Launch handling specifications will be published with the verified batch record. Protect the sealed research material from direct light in the interim.
Batch documentationSource review pending

Supplier-origin documentation will be published only after EternaGen verifies the source and record details.

Not yet published
Important research-use boundary

This catalogue entry describes a research material, not an approved therapeutic formulation. Published findings do not provide directions for personal use and cannot verify the safety or performance of a separately sourced material.

Explore the research

What has been studied?

Keep the context attached

Check what was studied, what researchers observed, and the limitation attached to each finding.

Question 01

Anxiety-related measures

A 62-person comparative study reported psychometric outcomes for Selank and medazepam in generalized anxiety disorder and neurasthenia.

Evidence so far: Small single-study human evidence
Question 02

Receptor-related signalling

Laboratory and animal work has examined GABA- and NMDA-receptor binding as possible explanatory pathways.

Evidence so far: Mechanistic and animal evidence
Question 03

Independent confirmation

The human evidence base is narrow, regionally concentrated and insufficient to establish broad efficacy or long-term safety.

Evidence so far: Major evidence gap

Proposed mechanism

How researchers are investigating the mechanism.

Laboratory studies have examined Selank in relation to enkephalin degradation and GABA-receptor binding. Animal experiments suggest that administration route and strain can materially change the observed signal, which limits broad interpretation.

Evidence gaps

What remains unknown?

  • Independent, adequately powered human trials with transparent safety reporting are lacking.
  • Long-term safety, pharmacokinetics and formulation comparability remain insufficiently characterized.
  • Mechanistic receptor findings do not establish a meaningful outcome in people.